Atea Pharma Form 4: RSU Conversion & New Option Grant to Director Lucidi

Rhea-AI Filing Summary

Atea Pharmaceuticals (AVIR) filed a Form 4 on 24 Jun 2025 for director Bruno Lucidi covering transactions dated 20 Jun 2025.

• Common stock acquired: 29,600 shares were issued upon the full vesting and conversion of previously granted restricted stock units (RSUs) at a cost of $0, raising Lucidi’s direct holdings to 112,750 shares.
• New equity grants: (i) 29,600 RSUs that vest in a single tranche on the earlier of the next annual shareholder meeting or the first anniversary of grant; (ii) 41,200 stock options with a $3.25 exercise price, vesting in 12 equal monthly installments through 20 Jun 2026 and expiring on 19 Jun 2035.
• No open-market purchases or sales were reported; all activity reflects equity incentive awards and conversions.

The filing indicates continued insider equity ownership alignment, with a modest increase in direct share count and fresh long-term option incentives.

Insights

Financial Analyst

TL;DR  Director received new RSUs and options; increased share ownership, no sales—impact appears routine and neutral.

The Form 4 shows standard board compensation actions: a one-year RSU grant and 10-year options at $3.25, plus the automatic conversion of a prior RSU award. Because the transactions involve no cash sales and represent a relatively small fraction of Atea’s outstanding shares, the market impact is limited. The additional 29.6k shares bring Lucidi’s stake to roughly 0.1-0.2% of a typical small-cap float, implying minimal dilution. From a governance standpoint the filings reinforce alignment but do not alter the investment thesis. Overall, the disclosure is informational rather than catalytic.

Insider Trade Summary

29,600 shares exercised/converted

Mixed 4 txns

Insider Lucidi Bruno

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	29,600	$0.00	--
Grant/Award	Stock Option (Right to Buy)	41,200	$0.00	--
Exercise	Restricted Stock Units	29,600	$0.00	--
Exercise	Common Stock	29,600	$0.00	--

Holdings After Transaction: Restricted Stock Units — 29,600 shares (Direct); Stock Option (Right to Buy) — 41,200 shares (Direct); Common Stock — 112,750 shares (Direct)

Footnotes (1)

1. Restricted stock units convert into common stock on a one-for-one basis. The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. The restricted stock units vested in full on June 20, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lucidi Bruno

(Last) (First) (Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		M		29,600	A	$0.00(1)	112,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/20/2025		A		29,600		(2)	(2)	Common Stock	29,600	$0.00	29,600	D
Stock Option (Right to Buy)	$3.25	06/20/2025		A		41,200		(3)	06/19/2035	Common Stock	41,200	$0.00	41,200	D
Restricted Stock Units	(1)	06/20/2025		M			29,600	(4)	(4)	Common Stock	29,600	$0.00	0	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

3. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

4. The restricted stock units vested in full on June 20, 2025.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Bruno Lucidi	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AVIR director Bruno Lucidi report?

Lucidi converted 29,600 vested RSUs into common stock and received 29,600 new RSUs and 41,200 stock options.

How many Atea Pharmaceuticals shares does Bruno Lucidi now own?

112,750 common shares are held directly after the reported transactions.

What is the exercise price and vesting schedule for the new stock options?

The options have a $3.25 exercise price and vest in 12 equal monthly installments beginning 20 Jun 2025, fully vesting in one year.

When will the newly granted RSUs to Bruno Lucidi vest?

They vest in a single tranche on the earlier of the next annual shareholder meeting or the first anniversary of 20 Jun 2025.

Did the insider sell any AVIR shares in this Form 4 filing?

No; all reported transactions were grants or conversions—no open-market sales occurred.